Early access
Sign in
Taking peoplePhase 1

Safety study of GRT-002 in healthy volunteers and people with chronic spontaneous urticaria

Tests how safe GRT-002 is in healthy volunteers and people with chronic spontaneous urticaria.

Key facts

Who runs it
Granite Bio AG
Where
Germany2 sites in 1 countryChoose a country to see its sites
Registry title
GRT-2U101: A randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-002 in healthy volunteers and patients with chronic spontaneous urticaria after single or multiple intravenous or subcutaneous dosing of GRT-002 (BASALT trial).
Status
Recruiting
Phase
Phase 1
People taking part
73 people, planned
Started
26 Sept 2026
Expected to end
15 Dec 2027
Type of study
Interventional
Record updated
9 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy volunteers and adults with chronic spontaneous urticaria (long-lasting hives with no known trigger). It tests the safety of GRT-002 given into a vein or under the skin.

Age
18 Years and older
Sex
All sexes
Disease stage
Chronic spontaneous urticaria (for the patient group)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Safety study of GRT-002 in healthy volunteers and people with chronic spontaneous urticariaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
9 September 2026